Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$72.3 million.

  • Autolus Therapeutics' Free Cash Flow rose 1624.25% to -$72.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$285.2 million, marking a year-over-year decrease of 3871.84%. This contributed to the annual value of -$228.3 million for FY2024, which is 4584.0% down from last year.
  • Per Autolus Therapeutics' latest filing, its Free Cash Flow stood at -$72.3 million for Q3 2025, which was up 1624.25% from -$80.1 million recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Free Cash Flow high stood at -$15.2 million for Q4 2022, and its period low was -$86.3 million during Q3 2024.
  • For the 5-year period, Autolus Therapeutics' Free Cash Flow averaged around -$45.8 million, with its median value being -$41.7 million (2023).
  • As far as peak fluctuations go, Autolus Therapeutics' Free Cash Flow surged by 5101.32% in 2021, and later tumbled by 10709.35% in 2024.
  • Autolus Therapeutics' Free Cash Flow (Quarter) stood at -$25.3 million in 2021, then skyrocketed by 39.89% to -$15.2 million in 2022, then crashed by 73.1% to -$26.3 million in 2023, then crashed by 86.42% to -$49.0 million in 2024, then tumbled by 47.43% to -$72.3 million in 2025.
  • Its last three reported values are -$72.3 million in Q3 2025, -$80.1 million for Q2 2025, and -$83.8 million during Q1 2025.